Happy Friday. Stock futures were rising Friday following a sharp sell-off, as Treasury’s efforts to bolster bond buybacks ...

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers, ...

Shares of Moderna Inc MRNA had their best day in history as a public company this week, with the stock soaring on positive ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Amid rising cancer burden in India, the mRNA custom-made cancer vaccine for melanoma has intriguing potential. ​While typical ...

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

The results, announced this week by Moderna and Merck, could pave the way for a new generation of treatments tailored to ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

The Centers for Disease Control and Prevention has brought on a communications and public affairs official who appears to ...

Early results from final-stage trial of individualised melanoma jab offer hope of more tailor-made cancer treatments ...

Moderna and Merck's personalised cancer vaccine succeeds in a Phase 3 trial, raising hopes for a new generation of cancer ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...